Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Arch Pharmalabs Ltd

    Arch Pharmalabs Ltd, originally incorporated in April 1993 as Merven Drug Products Pvt Ltd , is engaged in the manufacturing of Active Pharmaceutical Ingredients / intermediates

  • No Image
    Ashapura Minechem Ltd

    Established in 1960, Ashapura Group is India?s largest muti-mineral solutions provider. The flagship company Ashapura Minechem Ltd. is listed on India?s premier exchanges. Ashap

  • No Image
    Asian Clinical Trials Pvt Ltd

    Asian Clinical Trials Pvt Ltd is a contract research organization, provides clinical research solutions for pharmaceutical, biotechnology, and medical device companies. It offer

  • No Image
    Astec Lifesciences Ltd

    Astec LifeSciences Ltd is engaged in the manufacture and sale of intermediates, active ingredients and formulations, with a focus of the agrochemical sector. The manufacturing a

  • No Image
    Astrazeneca Pharma Ltd

    AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. It is present in seven crucial areas of healthcare - Cardiovascular, Diabetes, Oncology,